Notice Information
Notice Title
NHS Framework - Blood Disorders including Haemophilia A and B - July 2024
Notice Description
Project Title: NHS National Framework Agreement for the supply of products for the treatment of Blood Disorders including Haemophilia A and B - July 2024<br/><br/>Offer reference number: CM/PHS/22/5661<br/><br/>Period of framework: 1 July 2024 to 30 April 2027 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.<br/><br/>Published By: Medicines Procurement and Supply Chain - NHS Medicines Value & Access, NHS England
Lot Information
CM/PHS/22/5661/01 Standard Half-life Recombinant Factor VIII
Standard Half-life Recombinant Factor VIII
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIIICM/PHS/22/5661/02 Enhanced Half-life Recombinant Factor VIII
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/03 EmicizumabCM/PHS/22/5661/03 Emicizumab
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)CM/PHS/22/5661/04 eftrenonacog alfa (rFIX EHL)
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)CM/PHS/22/5661/05 albutrepenonacog alfa (rFIX EHL)
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)CM/PHS/22/5661/06 nonacog beta pegol (rFIX EHL)
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/07 rFIX - Standard Half LifeCM/PHS/22/5661/07 rFIX - Standard Half Life
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/08 Recombinant Factor VIICM/PHS/22/5661/08 Recombinant Factor VII
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfaCM/PHS/22/5661/09 Porcine Factor VIII - susoctocog alfa
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing FractionCM/PHS/22/5661/10 Factor VIII Inhibitor Bypassing Fraction
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/11 Factor IX - High Purity Factor IXCM/PHS/22/5661/11 Factor IX - High Purity Factor IX
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/12 Factor XCM/PHS/22/5661/12 Factor X
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/13 Factor XIII - Plasma DerivedCM/PHS/22/5661/13 Factor XIII - Plasma Derived
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/14 Factor XIII - RecombinantCM/PHS/22/5661/14 Factor XIII - Recombinant
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/15 Von willebrands factor / Factor VIIICM/PHS/22/5661/15 Von willebrands factor / Factor VIII
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/16 Von willebrands factor - Plasma DerivedCM/PHS/22/5661/16 Von willebrands factor - Plasma Derived
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/17 Von willebrands factor - RecombinantCM/PHS/22/5661/17 Von willebrands factor - Recombinant
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/18 Fibrinogen ConcentrateCM/PHS/22/5661/18 Fibrinogen Concentrate
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/19 Prothrombin Complex driedCM/PHS/22/5661/19 Prothrombin Complex dried
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/20 Protein C ConcentrateCM/PHS/22/5661/20 Protein C Concentrate
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/21 Fresh Frozen Plasma (all blood groups)CM/PHS/22/5561/21 Fresh Frozen Plasma (all blood groups)
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/22 Freeze Dried PlasmaCM/PHS/22/5661/22 Freeze Dried Plasma
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
CM/PHS/22/5661/23 CaplacizumabCM/PHS/22/5661/23 Caplacizumab
Options: Option or options to extend (at the Authority's discretion) for a period or periods up to a total of 14 months.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-043b0e
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/018011-2024
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Framework
- Procurement Category
- Goods
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large, SME
Common Procurement Vocabulary (CPV)
- CPV Divisions
33 - Medical equipments, pharmaceuticals and personal care products
-
- CPV Codes
33600000 - Pharmaceutical products
Notice Value(s)
- Tender Value
- £1,168,000,000 £1B-£10B
- Lots Value
- £23 Under £100K
- Awards Value
- Not specified
- Contracts Value
- £1
Notice Dates
- Publication Date
- 11 Jun 20242 years ago
- Submission Deadline
- 21 Mar 2024Expired
- Future Notice Date
- Not specified
- Award Date
- 31 May 20242 years ago
- Contract Period
- 1 Jul 2024 - 30 Apr 2027 2-3 years
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active, Unsuccessful
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS England
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- LEEDS
- Postcode
- LS2 7UE
- Postcode Area
- Leeds
- Country
- England
-
- Major Region (ITL 1)
- TLE Yorkshire and The Humber
- Basic Region (ITL 2)
- TLE4 West Yorkshire
- Small Region (ITL 3)
- TLE42 Leeds
- Delivery Location
- Not specified
-
- Local Authority
- Leeds
- Electoral Ward
- Little London & Woodhouse
- Westminster Constituency
- Leeds Central and Headingley
Further Information
Open Contracting Data Standard (OCDS)
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.